Showing results (151-160 of 176) with videos related to
Sort By:
Pageof 18
Internal Medicine (Tokyo, Japan)|September 3, 2025
The Efficacy and Safety of Atezolizumab Plus Bevacizumab after Durvalumab Plus Tremelimumab for the Treatment of Hepatocellular CarcinomaShinsuke Uchikawa, Tomokazu Kawaoka, Aiko Tanaka, et al.Clinical and Translational Gastroenterology|July 18, 2020
Tumor Fibroblast Growth Factor Receptor 4 Level Predicts the Efficacy of Lenvatinib in Patients With Advanced Hepatocellular CarcinomaMasami Yamauchi, Atsushi Ono, Akira Ishikawa, et al.Cellular and Molecular Gastroenterology and Hepatology|February 18, 2017
Circulating Tumor DNA Analysis for Liver Cancers and Its Usefulness as a Liquid BiopsyAtsushi Ono, Akihiro Fujimoto, Yujiro Yamamoto, et al.Therapeutic Advances in Medical Oncology|June 18, 2020
Circulating cytokines and angiogenic factors based signature associated with the relative dose intensity during treatment in patients with advanced hepatocellular carcinoma receiving lenvatinibAtsushi Ono, Hiroshi Aikata, Masami Yamauchi, et al.Hepatology Research : the Official Journal of the Japan Society of Hepatology|February 27, 2016
Effects of ITPA polymorphism on decrease of hemoglobin during simeprevir, peg-interferon, and ribavirin combination treatment for chronic hepatitis CKei Morio, Michio Imamura, Yoshiiku Kawakami, et al.Journal of Viral Hepatitis|July 13, 2018
CTL-associated and NK cell-associated immune responses induce different HBV DNA reduction patterns in chronic hepatitis B patientsMotonobu Nomura, Masataka Tsuge, Takuro Uchida, et al.Journal of Gastroenterology|July 26, 2017
Involvement of Porphyromonas gingivalis in the progression of non-alcoholic fatty liver diseaseTakashi Nakahara, Hideyuki Hyogo, Atsushi Ono, et al.Journal of Gastroenterology|November 9, 2016
ITPA polymorphism effects on decrease of hemoglobin during sofosbuvir and ribavirin combination treatment for chronic hepatitis CKei Morio, Michio Imamura, Yoshiiku Kawakami, et al.Plos One|August 11, 2017
The risks of hepatocellular carcinoma development after HCV eradication are similar between patients treated with peg-interferon plus ribavirin and direct-acting antiviral therapyYuko Nagaoki, Michio Imamura, Hiroshi Aikata, et al.BMC Cancer|November 29, 2022
Prevalence of immune-related adverse events and anti-tumor efficacy following immune checkpoint inhibitor therapy in Japanese patients with various solid tumorsYuki Yoshikawa, Michio Imamura, Masami Yamauchi, et al.Pageof 18